Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.

Effective, low-cost therapeutics are needed to prevent and treat COVID-19. Severe COVID-19 disease is linked to excessive inflammation. Disulfiram is an approved oral drug used to treat alcohol use disorder that is a potent anti-inflammatory agent and an inhibitor of the viral proteases. We investig...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nathanael Fillmore, Steven Bell, Ciyue Shen, Vinh Nguyen, Jennifer La, Maureen Dubreuil, Judith Strymish, Mary Brophy, Gautam Mehta, Hao Wu, Judy Lieberman, Nhan Do, Chris Sander
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e043e93b242c463fbbc7a2605d6b34e6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e043e93b242c463fbbc7a2605d6b34e6
record_format	dspace
spelling	oai:doaj.org-article:e043e93b242c463fbbc7a2605d6b34e62021-12-02T20:13:24ZDisulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.1932-620310.1371/journal.pone.0259061https://doaj.org/article/e043e93b242c463fbbc7a2605d6b34e62021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0259061https://doaj.org/toc/1932-6203Effective, low-cost therapeutics are needed to prevent and treat COVID-19. Severe COVID-19 disease is linked to excessive inflammation. Disulfiram is an approved oral drug used to treat alcohol use disorder that is a potent anti-inflammatory agent and an inhibitor of the viral proteases. We investigated the potential effects of disulfiram on SARS-CoV-2 infection and disease severity in an observational study using a large database of clinical records from the national US Veterans Affairs healthcare system. A multivariable Cox regression adjusted for demographic information and diagnosis of alcohol use disorder revealed a reduced risk of SARS-CoV-2 infection with disulfiram use at a hazard ratio of 0.66 (34% lower risk, 95% confidence interval 24-43%). There were no COVID-19 related deaths among the 188 SARS-CoV-2 positive patients treated with disulfiram, in contrast to 5-6 statistically expected deaths based on the untreated population (P = 0.03). Our epidemiological results suggest that disulfiram may contribute to the reduced incidence and severity of COVID-19. These results support carefully planned clinical trials to assess the potential therapeutic effects of disulfiram in COVID-19.Nathanael FillmoreSteven BellCiyue ShenVinh NguyenJennifer LaMaureen DubreuilJudith StrymishMary BrophyGautam MehtaHao WuJudy LiebermanNhan DoChris SanderPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10, p e0259061 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Nathanael Fillmore Steven Bell Ciyue Shen Vinh Nguyen Jennifer La Maureen Dubreuil Judith Strymish Mary Brophy Gautam Mehta Hao Wu Judy Lieberman Nhan Do Chris Sander Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.
description	Effective, low-cost therapeutics are needed to prevent and treat COVID-19. Severe COVID-19 disease is linked to excessive inflammation. Disulfiram is an approved oral drug used to treat alcohol use disorder that is a potent anti-inflammatory agent and an inhibitor of the viral proteases. We investigated the potential effects of disulfiram on SARS-CoV-2 infection and disease severity in an observational study using a large database of clinical records from the national US Veterans Affairs healthcare system. A multivariable Cox regression adjusted for demographic information and diagnosis of alcohol use disorder revealed a reduced risk of SARS-CoV-2 infection with disulfiram use at a hazard ratio of 0.66 (34% lower risk, 95% confidence interval 24-43%). There were no COVID-19 related deaths among the 188 SARS-CoV-2 positive patients treated with disulfiram, in contrast to 5-6 statistically expected deaths based on the untreated population (P = 0.03). Our epidemiological results suggest that disulfiram may contribute to the reduced incidence and severity of COVID-19. These results support carefully planned clinical trials to assess the potential therapeutic effects of disulfiram in COVID-19.
format	article
author	Nathanael Fillmore Steven Bell Ciyue Shen Vinh Nguyen Jennifer La Maureen Dubreuil Judith Strymish Mary Brophy Gautam Mehta Hao Wu Judy Lieberman Nhan Do Chris Sander
author_facet	Nathanael Fillmore Steven Bell Ciyue Shen Vinh Nguyen Jennifer La Maureen Dubreuil Judith Strymish Mary Brophy Gautam Mehta Hao Wu Judy Lieberman Nhan Do Chris Sander
author_sort	Nathanael Fillmore
title	Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.
title_short	Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.
title_full	Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.
title_fullStr	Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.
title_full_unstemmed	Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.
title_sort	disulfiram use is associated with lower risk of covid-19: a retrospective cohort study.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/e043e93b242c463fbbc7a2605d6b34e6
work_keys_str_mv	AT nathanaelfillmore disulfiramuseisassociatedwithlowerriskofcovid19aretrospectivecohortstudy AT stevenbell disulfiramuseisassociatedwithlowerriskofcovid19aretrospectivecohortstudy AT ciyueshen disulfiramuseisassociatedwithlowerriskofcovid19aretrospectivecohortstudy AT vinhnguyen disulfiramuseisassociatedwithlowerriskofcovid19aretrospectivecohortstudy AT jenniferla disulfiramuseisassociatedwithlowerriskofcovid19aretrospectivecohortstudy AT maureendubreuil disulfiramuseisassociatedwithlowerriskofcovid19aretrospectivecohortstudy AT judithstrymish disulfiramuseisassociatedwithlowerriskofcovid19aretrospectivecohortstudy AT marybrophy disulfiramuseisassociatedwithlowerriskofcovid19aretrospectivecohortstudy AT gautammehta disulfiramuseisassociatedwithlowerriskofcovid19aretrospectivecohortstudy AT haowu disulfiramuseisassociatedwithlowerriskofcovid19aretrospectivecohortstudy AT judylieberman disulfiramuseisassociatedwithlowerriskofcovid19aretrospectivecohortstudy AT nhando disulfiramuseisassociatedwithlowerriskofcovid19aretrospectivecohortstudy AT chrissander disulfiramuseisassociatedwithlowerriskofcovid19aretrospectivecohortstudy
_version_	1718374797610582016

Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.

Ejemplares similares